MX359882B - Amidas como moduladores de canales de sodio. - Google Patents

Amidas como moduladores de canales de sodio.

Info

Publication number
MX359882B
MX359882B MX2015009591A MX2015009591A MX359882B MX 359882 B MX359882 B MX 359882B MX 2015009591 A MX2015009591 A MX 2015009591A MX 2015009591 A MX2015009591 A MX 2015009591A MX 359882 B MX359882 B MX 359882B
Authority
MX
Mexico
Prior art keywords
amidas
modulators
sodium channels
pharmaceutically acceptable
compositions
Prior art date
Application number
MX2015009591A
Other languages
English (en)
Other versions
MX2015009591A (es
Inventor
Sabina Hadida-Ruah Sara
Richard Bear Brian
Arumugam Vijayalaksmi
Anderson Corey
Luci Asgian Iuliana
P Termin Andreas
Philip Johnson James
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2015009591A publication Critical patent/MX2015009591A/es
Publication of MX359882B publication Critical patent/MX359882B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se relaciona con compuestos de amida de fórmula I y I' o sales farmacéuticamente aceptables de los mismos, útiles como inhibidores de canales de sodio: (ver Fórmulas) La invención también proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la invención y métodos de uso de las composiciones en el tratamiento de varios trastornos, incluyendo el dolor.
MX2015009591A 2013-01-31 2014-01-29 Amidas como moduladores de canales de sodio. MX359882B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759062P 2013-01-31 2013-01-31
PCT/US2014/013667 WO2014120820A1 (en) 2013-01-31 2014-01-29 Amides as modulators of sodium channels

Publications (2)

Publication Number Publication Date
MX2015009591A MX2015009591A (es) 2016-04-15
MX359882B true MX359882B (es) 2018-10-15

Family

ID=50114569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009591A MX359882B (es) 2013-01-31 2014-01-29 Amidas como moduladores de canales de sodio.

Country Status (15)

Country Link
US (2) US9108903B2 (es)
EP (1) EP2951155B1 (es)
JP (1) JP6346622B2 (es)
KR (1) KR102226588B1 (es)
CN (1) CN104968647B (es)
AR (1) AR094668A1 (es)
AU (1) AU2014212431B2 (es)
BR (1) BR112015018284B1 (es)
CA (1) CA2898653C (es)
IL (1) IL240196B (es)
MX (1) MX359882B (es)
RU (1) RU2658920C2 (es)
SG (1) SG11201505954RA (es)
TW (1) TWI659945B (es)
WO (1) WO2014120820A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857687T3 (es) 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
PE20160548A1 (es) 2013-07-19 2016-05-21 Vertex Pharma Sulfonamidas como moduladores de canales de sodio
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CA3069720A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2019157505A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
KR102860523B1 (ko) 2018-11-02 2025-09-16 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드
BR112021012909A2 (pt) * 2019-01-04 2021-09-14 Jiangsu Hengrui Medicine Co., Ltd. Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN112996776B (zh) * 2019-02-20 2024-03-15 福建盛迪医药有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
TWI770607B (zh) * 2019-09-12 2022-07-11 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物及其製備方法和用途
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
EP4167994A4 (en) 2020-06-17 2024-07-24 Merck Sharp & Dohme LLC 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS
JP7323723B2 (ja) 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN114031518B (zh) * 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
CN112225695B (zh) * 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
JP2024509939A (ja) * 2021-03-11 2024-03-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド ピリジン窒素酸化物の結晶形態およびその使用
MX2023013146A (es) 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
JP2024520646A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
CN119487003A (zh) 2022-04-22 2025-02-18 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
AU2023255771A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GEAP202516637A (en) 2022-04-25 2025-03-25 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
TW202434235A (zh) * 2023-01-18 2024-09-01 芬蘭商奧利安公司 ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法
AU2024367861A1 (en) 2023-10-23 2026-05-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2024365648A1 (en) 2023-10-23 2026-04-30 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2511231A (en) 1949-03-26 1950-06-13 Eastman Kodak Co 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
AU2008310663A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP5555169B2 (ja) 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
CN105254557A (zh) * 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物

Also Published As

Publication number Publication date
NZ710293A (en) 2020-09-25
MX2015009591A (es) 2016-04-15
HK1217692A1 (en) 2017-01-20
AU2014212431A1 (en) 2015-08-06
JP2016508500A (ja) 2016-03-22
KR102226588B1 (ko) 2021-03-11
EP2951155B1 (en) 2019-06-19
WO2014120820A9 (en) 2015-07-02
TWI659945B (zh) 2019-05-21
KR20150118964A (ko) 2015-10-23
SG11201505954RA (en) 2015-08-28
CA2898653C (en) 2021-09-28
US9421196B2 (en) 2016-08-23
US20150328196A1 (en) 2015-11-19
CN104968647B (zh) 2018-01-26
EP2951155A1 (en) 2015-12-09
RU2015136779A (ru) 2017-03-07
US9108903B2 (en) 2015-08-18
AR094668A1 (es) 2015-08-19
BR112015018284A2 (pt) 2017-07-18
US20140221435A1 (en) 2014-08-07
CA2898653A1 (en) 2014-08-07
CN104968647A (zh) 2015-10-07
WO2014120820A1 (en) 2014-08-07
IL240196B (en) 2019-08-29
IL240196A0 (en) 2015-09-24
TW201443005A (zh) 2014-11-16
JP6346622B2 (ja) 2018-06-20
BR112015018284B1 (pt) 2023-03-07
RU2658920C2 (ru) 2018-06-26
AU2014212431B2 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CO2019013021A2 (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
CR20140135A (es) Nuevos derivados de aril-quinolina
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX378012B (es) Compuestos de alquinil dihidroquinolina sulfonamida.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену
CL2012001818A1 (es) Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis.

Legal Events

Date Code Title Description
FG Grant or registration